A Phase 2 clinical trial is testing the effectiveness of Mestinon (pyridostigmine…
Ana Pena, PhD
Ana is a molecular biologist with a passion for communication and discovery. As a science writer, her goal is to provide readers, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
Psychological Support Relieves Anxiety of Spinraza Treatment in Kids With SMA Type 1, Study Says
Psychological interventions to control emotional stress can help relieve the anxiety that parents and children with…
A newly identified mutation in the DYNC1H1 gene causes a rare form…
Spinal muscular atrophy (SMA) patients can be more prone to a life-threatening metabolic imbalance called ketoacidosis,…
Protein Independent of SMN May Be Worthy Target as Combo Treatment for SMA, Mouse Study Suggests
Lowering the levels of a protein called CHP1, together with Spinraza (nusinersen) treatment, may help to…
A key player in a pathway known as the cell’s “cleaning system” could be a promising target for alternative approaches…
A pathway known as the cell’s “cleaning system” may be a promising target of alternative approaches to treating…
Neurological health depends as much on signals sent by the body’s leg muscles to the brain as it does on…
AVXS-101 has been awarded the SAKIGAKE designation in Japan for the treatment of spinal muscular atrophy (SMA) type…
Many parents of children with neuromuscular disorders like SMA would like to see if yet-to-be-approved therapies could help…